What Is Infliximab (Ocular Uveitis)?

How Does Infliximab Work to Suppress Ocular Inflammation?

Uveitis is caused by the immune system mistakenly attacking the vascular tissues inside the eye. Infliximab acts like a biological sponge, soaking up and neutralizing the TNF-alpha molecules before they can reach the eye and cause damage. By shutting down this primary inflammatory signal, the medication allows the eye to heal and prevents the formation of permanent scars on the retina. Because it is a large protein molecule, it must be administered as an intravenous infusion in a medical setting every six to eight weeks.

What are the Primary Success Data for Refractory Uveitis?

Clinical data indicates that Infliximab is one of the most effective treatments for refractory uveitis, which is inflammation that does not respond to standard care. Studies show that over 80 percent of patients with Behçet’s related uveitis achieve total remission within the first few months of treatment. Furthermore, Infliximab is highly effective at reducing macular edema, a common complication that causes central vision loss. These data trends have established Infliximab as a cornerstone of management for patients who are at a high risk of losing their vision.

Why is Initial Tuberculosis and Infection Screening Mandatory?

Because Infliximab suppresses a major part of the immune system, it can allow hidden infections to become active. Before starting the first infusion, all patients must undergo a chest X-ray and a blood test for tuberculosis and Hepatitis B. If a patient has a latent infection, the medication could cause it to spread rapidly throughout the body. This rigorous screening process is a mandatory safety protocol that ensures the benefits of the treatment far outweigh the systemic risks.

What are the Common Side Effects and Infusion Protocols?

Infliximab is generally well-tolerated, but patients must be monitored during the infusion for any signs of an allergic reaction. Common side effects include mild fatigue, headache, or a higher susceptibility to upper respiratory infections. The infusion itself takes about two hours and is performed in an infusion center under the supervision of a nurse. A loading dose schedule is typically followed, with infusions at week zero, two, and six, followed by a maintenance dose every two months to keep the eye inflammation in remission.

How Do Clinicians Use Infliximab to Achieve Spectacle Independence?

By controlling the underlying inflammation, Infliximab often allows patients to achieve a level of visual stability they haven't had in years. When the eye is no longer constantly red and swollen, the visual acuity often improves significantly, sometimes allowing the patient to return to driving or reading standard print. While the primary goal is to prevent blindness, the improvement in daily functional vision is a major driver of patient satisfaction. The long-term stability provided by biologics has completely changed the prognosis for what were once considered untreatable eye diseases.